medigraphic.com
ISSN 2395-8723 (Electronic)
ISSN 1405-888X (Print)
TIP Revista Especializada en Ciencias Químico-Biológicas

2011, Number 1

<< Back

TIP Rev Esp Cienc Quim Biol 2011; 14 (1)

Panorama actual del estudio de las plantas con actividad anti-Helicobacter pylori

Palacios-Espinosa F, Escobedo-Hinojosa W, Romero I

Language: Spanish
References: 72
Page: 51-61
PDF size: 127.03 Kb.


ABSTRACT

Helicobacter pylori is recognized as the major etiological agent of chronic active gastritis, peptic ulcer, as well as a predisposing factor in gastric carcinoma. It is estimated that over 50% of the population is infected by this bacterium and, in the case of Mexico, a 66% seroprevalence is reported. The current eradication treatment fails in more than 20% of cases, mainly due to resistance generated to commercial antibiotics. Thus, in order to control these diseases, it is important to find new treatments and/or compounds, more specific, less toxic, and easily accessible to the population. Plant natural products are potential sources for the discovery and development of new anti-H. pylori agents. This paper presents the state of the art on world research in this regard. It covers topics such as preliminary evaluation of plant extracts (screenings), the isolation of pure compounds from bioactive extracts, the elucidation of the probable mechanism of action, comprehensive studies evaluating anti-inflammatory and gastroprotective properties, and finally, chemical modification of prototype compounds.


REFERENCES

  1. Marsall, B.J. & Warren, J.P. Unidentified curved bacilli in the stomach patients with gastritis and peptic ulceration. Lancet 1, 1311-1315 (1984).

  2. Goodwin, C.S. et al. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., respectively. Int. J. Syst. Bacteriol. 39, 397-405 (1989).

  3. Pajares, J.M. & Gisbert, J.P. Helicobacter pylori: its discovery and relevance for medicine. Rev. Esp. Enferm. Dig. 98, 770-785 (2006).

  4. O´Rourke, J. & Bode, G. Morphology and Ultrastructure. In: Helicobacter pylori. Physiology and Genetics. (eds. Mobley, H. L. T., Mendz, G. L. & Hazell, S. L.) 53-67 (ASM Press Washington, 2001).

  5. Ogura, K. et al. Virulence factors of Helicobacter pylori responsible for gastric diseases in mongolian gerbil. J. Exp. Med. 192, 1601- 1609 (2000).

  6. Amieva, M.R. & El-Omar, E.M. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterol. 134, 306-323 (2008).

  7. Falkow, S. Perspectives series: host/pathogen interactions. Invasion and intracellular sorting of bacteria: searching for bacterial genes expressed during host/pathogen interactions. J. Clin. Invest. 100, 239-243 (1997).

  8. Atherton, J.C. The Pathogenesis of Helicobacter pylori–Induced Gastro-Duodenal Diseases. Annu. Rev. Pathol. Mech. Dis. 1, 63-96 (2006).

  9. Pérez-Pérez, G.I., Rothenbacher, D. & Brenner, H. Epidemiology of Helicobacter pylori infection. Helicobacter 9, 1-6 (2004).

  10. Taylor, D. & Parsonnet, J. Epidemiology and natural history of H. pylori infections of the gastrointestinal tract. En: Blaser, M.J., Smith, P.F., Ravdin, J., Greenberg, H. & Guerrant, R.L. 551-564 (Raven Press, New York, 1995).

  11. Torres, J. et al. A community-based seroepidemiologic study of Helicobacter pylori infection in México. J. Infect. Dis. 178, 1089-1094 (1998).

  12. Mitchell, H.M. Epidemiology of Infection. In: Helicobacter pylori. Physiology and Genetics (eds. Mobley, H.L.T., Mendz, G.L. & Hazell, S.L.) 7-18 (ASM Press, Washington, 2001).

  13. Kusters, J.G., van Vliet, A.H. & Kuipers, E.J. Pathogenesis of Helicobacter pylori Infection. Clin. Microbiol. Rev. 19, 449- 490 (2006).

  14. IARC (International Agency for Research on Cancer). Live flukes and Helicobacter pylori. IARC. Working group on the evaluation of Carcinogenic Risks to Human, Lyon, 7-14 June 1994. IARC Monogr. Eval. Carcinog. Risks. Hum. 61, 1-241 (1994).

  15. Mégraud, F. Strategies to treat patients with antibiotic resistant Helicobacter pylori. Internat. J. of Antimicr. Agents 16, 507– 509 (2000).

  16. Wannmacher, L. Review of the evidence for H. pylori treatment regimens. In Technical report series. pp. 33. Report of 18th expert committee on the selection and use of essential medicines. (WHO, 2011).

  17. Malfertheiner, P. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56, 772-781 (2007).

  18. Gisbert, J.P. “Rescue” regimens after Helicobacter pylori treatment failure. World J. Gastroenterol. 14, 5385-5402 (2008).

  19. Vakil, N. & Mégraud, F. Eradication Therapy for Helicobacter pylori. Reviews in basic and clinical Gastroenterology. Gastroenterol. 133, 985-1001 (2007).

  20. Mégraud, F. Helicobacter pylori and antibiotic resistance. Gut 56, 1502 (2007).

  21. Mégraud, F. & Corti, R. Resistencia bacteriana del Helicobacter pylori en el mundo en el año 2009. Acta Gastroenterol. Latinoam. 39, 282-290 (2009).

  22. Horiki, N. et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 14, 86-90 (2009).

  23. Chihu, L. et al. Antimicrobial resistance and characterization of Helicobacter pylori strains isolated from Mexican adults with clinical outcome. J. Chemother. 17, 270-276 (2005).

  24. Lopes, A.I. et al. Antibiotic-resistant Helicobacter pylori strains in Portuguese children. J. Pediatr. Infect. Dis.24, 404-409 (2005).

  25. Fujimura, S. et al. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J. Med. Microbiol. 53, 1019-1022 (2004).

  26. Glocker, E., Bogdan, C. & Kist, M. Characterization of rifampicin resistant clinical Helicobacter pylori isolates from Germany. J. Antimicrob. Chemother. 59, 874-879 (2008).

  27. Rautelin, H., Seppälä, K., Renkonen, O.V., Vainio, U. & Kosunen, T.U. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob. Agents Chemother. 36, 163-166 (1992).

  28. Graham, D.Y. et al. A report card to grade Helicobacter pylori therapy. Helicobacter 12, 275-278 (2007).

  29. Ford, A. et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients (rev). Cochrane Database Syst. Rev. 2006:CD003840.

  30. Shahid, M. et al. Plant natural products as a potential source for antibacterial agents: Recent trends. Curr. Med. Chem. 8, 211- 225 (2009).

  31. O´Connor, A., Gisbert, J. & O´Morain, C. Treatment of Helicobacter pylori infection. Helicobacter. 14, 46-51 (2009).

  32. Ghisalberti, E.L. Detection and isolation of bioactive natural products. In: Bioactive natural products: Detection, isolation, and structural determination. (eds. Colegate, S.M. & Molyneux, R.J.) 11-76 (Taylor & Francis Group, New York, 2008).

  33. Nariman, F., Eftekhar, F., Habibi, Z. & Falsafi, T. Anti-Helicobacter pylori activities of six Iranian plants. Helicobacter 9, 146-151 (2004).

  34. Li, Y., Xu, C., Zhang, Q., Liu, J.Y. & Tan, R.X. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer disease. J. Ethnopharmacol. 98, 329-333 (2005).

  35. Wang, Y.C. & Huang, T.L. Screening of anti-Helicobacter pylori herbs deriving from Taiwanese folk medicinal plants. FEMS Immunol. Med. Microb. 43, 295-300 (2005).

  36. Nostro, A. et al. Antibacterial effect of plant extracts against Helicobacter pylori. Phytother. Res. 19, 198-202 (2005).

  37. Zaman, R., Akhtar, M.S. & Khan, M.S. In vitro antibacterial screening of Anethum graveolens L. Fruit, Cichorium intybus L. Leaf, Plantago ovata L. Seed Husk and Polygonum viviparum L. Root extracts against Helibacter pylori. Int. J. Pharmacol. 2, 674-677 (2006).

  38. Ndip, R.N. et al. In vitro anti-Helicobacter pylori activity of extracts of selected medicinal plants from North West Cameroon. J. Ethnopharmacol. 114, 452-457 (2007).

  39. Zaidi, S. F. et al. Bactericidal activity of medicinal plants, employed for treatment of gastrointestinal ailments, against Helicobacter pylori. J. Ethnopharmacol. 121, 286-291 (2009).

  40. Atapor, M. et al. In vitro susceptibility of the Gram negative bacterium Helicobacter pylori extracts of Iranian medicinal plants. Pharm. Biol. 47, 77-80 (2009).

  41. Ankli, A. et al. Yucatec Mayan medicinal plants: evaluation based on indigenous uses. J. Ethnopharmacol. 79, 43-52 (2002).

  42. Castillo-Juárez, I., Rivero-Cruz, F., Celis, H. & Romero, I. Anti- Helicobacter pylori activity of anacardic acids from Amphipterygium adstringens. J. Ethnopharmacol. 114, 72-77 (2007).

  43. Castillo-Juárez, I. et al. Anti-Helicobacter pylori activity of plants used in Mexican traditional medicine for gastrointestinal disorders. J. Ethnopharmacol. 122, 402-405 (2009).

  44. Kawase, M. & Motohashi, N. Plant-derived leading compounds for eradication of Helicobacter pylori. Curr. Med. Chem. 3, 89-100 (2004).

  45. Castillo-Juárez, I. & Romero, I. Plantas con actividad anti-H. pylori: una revisión. Bol. Soc. Bot. Mex. 80, 35-61 (2007).

  46. Mabe, K., Yamada, M., Oguni, I. & Takahashi, T. In vitro and in vivo activities of tea catechins against Helicobacter pylori. Antimicr. Agents Chemother. 43, 1788-1791 (1999).

  47. Koga, T. et al. Effect of plaunotol in combination with clarithromycin or amoxicillin on Helicobacter pylori in vitro and in vivo. J. Antimicr. Chemother. 50, 133-136 (2002).

  48. Tominaga, K. et al. In vivo action of novel alkyl methyl quinolone alkaloids against Helicobacter pylori. J. Antimicr. Chemother. 50, 547-552 (2002).

  49. Kataoka, M. et al. Antibacterial action of tryptanthrin and kaempferol, isolated from the indigo plant (Polygonum tinctorium Lour.), against Helicobacter pylori-infected mongolian gerbils. J. Gastroenterol. 36, 5-9 (2001).

  50. Haristoy, X., Angioi-Duprez, K., Duprez, A. & Lozniewski, A. Efficacy of sulforaphane in eradicating Helicobacter pylori in human gastric xenografts implanted in nude mice. Antimic. Agents Chemother. 47, 3982-3984 (2003).

  51. Lima, Z.P. et al. Byrsonima fagifolia: An integrative study to validate the gastroprotective, healing, antidiarrheal, antimicrobial and mutagenic action. J. Ethnopharmacol.120, 149-160 (2008).

  52. Moraes, T.M. et al. Hancornia speciosa: indication of gastroprotective, healing and anti-Helicobacter pylori actions. J. Ethnopharmacol. 120, 161-168 (2008).

  53. Cruz, M. et al. Mouriri elliptica: Validation of gastroprotective, healing and anti-Helicobacter pylori effects. J. Ethnopharmacol. 123, 359-368 (2009).

  54. Kushima, H. et al., Davilla elliptica and Davilla nitida: Gastroprotective, anti-inflammatory immunomodulatory and anti-Helicobacter pylori action. J. Ethnopharmacol. 123, 430- 438 (2009).

  55. Quílez, A. et al. Anti-secretory, anti-inflammatory and anti- Helicobacter pylori activities of several isolated from Piper carpunya Ruiz & Pav. J. Ethnopharmacol. 128, 583-589 (2010).

  56. Mazzolin, L.P. et al. Qualea parvifolia Mart: An integrative study to validate the gastroprotective, antidiarrheal, antihemorragic and mutagenic action. J. Ethnopharmacol.127, 508-514 (2010).

  57. Kang, M.H. et al. Antigastritic and anti-Helicobacter pylori of trifolirhizin from Sophora radix. Korean J. Pharmacog. 37, 266-271 (2006).

  58. Williamson, E., Okpako, D.T. & Evans, F.J. Selection, preparation and pharmacological evaluation of plant material (John Wiley and Sons, New York, 1996).

  59. Watanabe, T., Tada, M., Nagai, H., Sasaki, S. & Masafumi, N. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterol. 115, 642-648 (1998).

  60. Ikeno, T. et al. Helicobacter pylori-induced chronic active gastritis, intestinal metaplasia, and gastric ulcer in mongolian gerbils. Am. J. Pathol. 154, 951-960 (1999).

  61. Nakagawa, S., Osaki, T., Fujioka, Y., Yamaguchi, H. & Kamiya, S. Long-term infection of Mongolian gerbils with Helicobacter pylori microbiological, histopathological, and serological analyses. Clin. Diagn. Lab. Immunol. 12, 47-53 (2005).

  62. Xiao, Z.P. et al. Polyphenols based on isoflavones as inhibitors of Helicobacter pylori urease. Bioorg. Med. Chem. 15, 3703-3710 (2007).

  63. Yahiro, K. et al. Inhibitory effects of polyphenols on gastric injury by Helicobacter pylori VacA toxin. Helicobacter 10, 231-239 (2005).

  64. Rho, T.C., Bae, E.A., Kim, D., Oh, W., Kim, B. & Lee, H. Anti- Helicobacter pylori activity of quinolone alkaloids from Evodiae fructus. Biolog. & Pharmaceut. Bulletin 22, 1141-1143 (1999).

  65. Matsubara, S. et al. Suppression of Helicobacter pylori-induced gastritis by green tea extract in Mongolian gerbils. Biochem. Biophy. Res. Comm. 310, 715-719 (2003).

  66. Wittschier, N. et al. Large molecules as anti-adhesive compounds against pathogens. J. Pharm. Pharmacol. 59, 777-786 (2007).

  67. Takagi, A. et al. Plaunotol suppresses interleukin-8 secretion induced by Helicobacter pylori: therapeutic effect of plaunotol on H. pylori infection. J. Gastroenterol. Hepatol. 15, 374-380 (2000).

  68. Lee, J.H., Park, E.K., Uhm C.S., Chung, M.S. & Kim, K.H. Inhibition of Helicobacter pylori adhesion to human gastric adenocarcinoma epithelial cells by acidic polysaccharides from Artemisia capillaris and Panax ginseng. Planta Medica70, 615-619 (2004).

  69. Lee, J.H. et al. In vivo anti-adhesive activity of green tea extract against pathogen adhesion. Phytother. Res. 23, 460-466 (2009).

  70. Xu, C. et al. Anti-adhesive effect of an acidic polysaccharide from Aloe vera L. var. chinensis (Haw.). Berger on the binding of Helicobacter pylori to the MKN-45 cell line. J. Phar. Pharmacol. 62, 1753-1759 (2010).

  71. Chimenti, F. et al. A novel class of selective anti-Helicobacter pylori agents 2-oxo-2H-chromene-3-carboxamide derivatives. Bioorg. Med. Chem. 16, 6179-6185 (2008).

  72. Zhu, H.L. et al. Metronidazole-Flavonoid derivatives as anti-Helicobacter pylori agents with potent inhibitory activity against HPE-Induced Interleukin-8 production by AGS cells. Chem. Med. Chem. 2, 1361-1369 (2007).




2020     |     www.medigraphic.com